QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer 期刊论文 INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2 作者:  Ouyang, Xuenong;  Shi, Meiqi;  Jie, Fangwei;  Bai, Yuxian;  Shen, Peng 收藏  |  浏览/下载：28/0  |  提交时间：2019/12/05 Phase III  Dulanermin  NSCLC  Progression-free survival  Objective response rate   Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer 期刊论文 INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2 作者:  Ouyang, Xuenong;  Shi, Meiqi;  Jie, Fangwei;  Bai, Yuxian;  Shen, Peng 收藏  |  浏览/下载：26/0  |  提交时间：2019/12/05 Phase III  Dulanermin  NSCLC  Progression-free survival  Objective response rate   Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer 期刊论文 INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2, 页码: 315-322 作者:  Ouyang, Xuenong;  Shi, Meiqi;  Jie, Fangwei;  Bai, Yuxian;  Shen, Peng 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/11 Phase III  Dulanermin  NSCLC  Progression-free survival  Objective  response rate